ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1992

Adenosine A2A Receptor (A2AR) Stimulation Mitigates Mitochondrial Inflammaging, Enhances Mitochondrial Metabolism and Reduces Reactive Oxygen Species-Mediated Mitochondrial Injury In Vitro and In Vivo in Osteoarthritis

Cristina Castro1, Carmen Corciulo 2, Maria Solecio 3, Benjamin Friedman 4, Fengxia Liang 5, Zhi Li 6, Samson Jacob 7, David Fenyo 8, Evgeny Pavlov 9 and Bruce Cronstein 4, 1Immunology and Inflammation Training Program at Skirball Institute of Graduate Biomolecular Sciences, New York University School of Medicine (NYUSoM), NYC, 2Division of Translational Medicine NYUSoM, NYC, 3NYU College of Dentistry, NYC, 4Department of Medicine, Division of Rheumatology NYUSoM, NYC, 5Department of Cell Biology, NYU Langone Health, NYC, 6Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU Langone Helalth, NYC, 7Institute for Systems Genetics, NYU Langone Health, NYC, 8Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYC, 9Basic Science and Craniofacial Biology, NYU College of Dentistry, NYC

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Aging and autophagy, Inflammation, Mitochondria, ROS

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, affecting nearly 10% of the US population and one of the contributing factors in OA pathogenesis is inflammaging, chronic low grade inflammation. With injury and aging there is dysfunction of chondrocyte mitochondria, thought to be a central event in inflammaging, resulting in reduction of intracellular and extracellular ATP and extracellular adenosine.  Reductions in extracellular adenosine or loss of A2AR leads to the development of OA. We therefore explored determined whether A2AR ligation regulates mitochondrial health in vivo and in vitro.

Methods: Primary murine WT and A2ARKO as well as primary human chondrocytes were isolated from neonatal mice or differentiated from surgical discard, treated with medium (CTRL) or IL-1β (5ng/mL for 4h) with and without the A2AR agonist, CGS21680 (1uM for 1h, CGS) or CGS alone and then stained with TMRM to evaluate mitochondrial length, network volumes and membrane polarity. RNAseq, RT-PCR and transmission electron microscopy (TEM) were performed in untreated murine chondrocytes and proteins of interest were evaluated by WB. Mitochondrial markers were also evaluated in rat post-traumatic OA (PTOA) and mouse obesity-induced OA (OB-OA) modelsin vivo. Human chondrocytic cells (T/C28-a2) were grown in culture, treated as stated above and submitted for TEM to study mitochondrial ultrastructure. Primary human chondrocytes were cultured from discarded surgical specimens.

Results: WT chondrocytes treated with CGS +/- IL-1β had increased mitochondrial lengths than cells that received medium or IL-1β alone (p< 0.0001, ONE-Way ANOVA). There were no significant differences in mitochondrial lengths of untreated WT or null chondrocytes but loss of A2AR signaling prevented mitochondrial length expansion after stimuli (p< 0.04, ONE-Way ANOVA). Depolarization upregulates total PINK1 expression in A2AR-/-  (p< 0.005, unpaired, two-tailed t-test) but not Parkin levels. ROS burden was reduced and mitochondrial markers were improved in PTOA and OB-OA models in vivo. In fully differentiated human chondrocytes, A2AR ligation after stimulation with IL-1β increased TMRM and mitochondrial volumes (p< 0.0001, ONE-Way ANOVA). T/C28-a2 cells treated with CGS after IL-1β exposure had significantly reduced cristae widths (p< 0.0001) and an increased number of cristae junctions per mitochondria (p=0.02, ONE-Way ANOVA).

Conclusion: A2AR ligation enhances mitochondrial function and biomass in murine chondrocytes in vitroand in vivo in models of OA and, thereby diminishes the signs of inflammaging, maintains chondrocyte homeostasis and reverses OA in vivo.


Disclosure: C. Castro, None; C. Corciulo, None; M. Solecio, None; B. Friedman, None; F. Liang, None; Z. Li, None; S. Jacob, None; D. Fenyo, None; E. Pavlov, None; B. Cronstein, Abbott, 4, Amgen, AstraZeneca, 5, Baxter, 4, Bristol-Myers Squibb, 4, CanFite Biopharma, 4, Eli Lilly & Co, 5, Gilead, 4, Horizon Pharmaceuticals, 5, NIH, Arthritis Foundation, Kairos, 2, Novartis, 4, Patent Pending for the use of adenosine receptor agonists for the treatment of OA, Patents pending for use of adenosine receptor agonist and antagonist for treatment of bone, liver diseases and wound healing, Regenosine, 4, Regenosine, Inc, 4, 6.

To cite this abstract in AMA style:

Castro C, Corciulo C, Solecio M, Friedman B, Liang F, Li Z, Jacob S, Fenyo D, Pavlov E, Cronstein B. Adenosine A2A Receptor (A2AR) Stimulation Mitigates Mitochondrial Inflammaging, Enhances Mitochondrial Metabolism and Reduces Reactive Oxygen Species-Mediated Mitochondrial Injury In Vitro and In Vivo in Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/adenosine-a2a-receptor-a2ar-stimulation-mitigates-mitochondrial-inflammaging-enhances-mitochondrial-metabolism-and-reduces-reactive-oxygen-species-mediated-mitochondrial-injury-in-vitro-and-in-vivo/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-a2ar-stimulation-mitigates-mitochondrial-inflammaging-enhances-mitochondrial-metabolism-and-reduces-reactive-oxygen-species-mediated-mitochondrial-injury-in-vitro-and-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology